Search - tctmd.com

Displaying 121 - 131 of 131

Presentation TCT 2012

Clopidogrel Hyporesponsiveness, Interacting with Diabetes Mellitus, Predicts 2-Year Cardiovascular Outcome Among Taiwanese Population Underging Percutaneous Coronary Intervention

Presenter: Ping-Yen Liu, Ling-Jay Hsu, Po-Tseng Lee, Cheng-Hann Lee, Ju-Yi Chen, Yi-Heng Li, Liang-Miin Tsai, Jyh-Hong Chen

January 03, 2012

News Conference News

SPICE: Esomeprazole Reduces Antiplatelet Effect of Clopidogrel

November 21, 2011

News Conference News

Prasugrel Bests Double Clopidogrel Dose for STEMI Patients with High Residual Platelet Reactivity

November 17, 2011

News Conference News

RAPID GENE: Validation of Point-of-Care Genetic Testing

November 09, 2011

News Conference News

PARIS: Early DAPT Nonadherence, A Small Problem with Big Consequences

November 09, 2011

News Conference News

BRIDGE: Cangrelor Provides Effective Maintenance of Platelet Inhibition Without Major Bleeding

November 09, 2011

News Conference News

ADAPT-DES: Risk of Early Stent Thrombosis in DES Predicted by Platelet Inhibition

November 09, 2011

News Conference News

ZES and SES Equally Effective in Long Lesion Treatment

November 08, 2011

News Conference News

Mock Jury Votes on DAPT Duration: 12 Months Remains Best Option for Most Patients

November 08, 2011

News Conference News

SAT-TAVI: Data Support TAVR Without Dual Antiplatelet Therapy

November 07, 2011

News Conference News

Prasugrel, Ticagrelor Reduced Incidence of Stent Thrombosis

November 06, 2011

Advertisement

Clopidogrel Hyporesponsiveness, Interacting with Diabetes Mellitus, Predicts 2-Year Cardiovascular Outcome Among Taiwanese Population Underging Percutaneous Coronary Intervention

SPICE: Esomeprazole Reduces Antiplatelet Effect of Clopidogrel

Prasugrel Bests Double Clopidogrel Dose for STEMI Patients with High Residual Platelet Reactivity

RAPID GENE: Validation of Point-of-Care Genetic Testing

PARIS: Early DAPT Nonadherence, A Small Problem with Big Consequences

BRIDGE: Cangrelor Provides Effective Maintenance of Platelet Inhibition Without Major Bleeding

ADAPT-DES: Risk of Early Stent Thrombosis in DES Predicted by Platelet Inhibition

ZES and SES Equally Effective in Long Lesion Treatment

Mock Jury Votes on DAPT Duration: 12 Months Remains Best Option for Most Patients

SAT-TAVI: Data Support TAVR Without Dual Antiplatelet Therapy

Prasugrel, Ticagrelor Reduced Incidence of Stent Thrombosis

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content